TCMD
TactileANasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-22
Current thesis
Strong Q1 growth, improved gross margin and positive adjusted EBITDA indicate better operating leverage. MyoSleeve, AffloVest, LymphaTech, and reimbursement capabilities broaden the platform, while the $39.50 median analyst target implies upside from the $28.60 anchor price.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
Low analyst coverage and limited forward-estimate visibility.
Momentum
69
Value
60
Sentiment
59
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $30.00 · Bull $39.50 · Bear $24.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-23 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $39.50
Why
Momentum69 · Δ7d +6.4
Value60 · Δ7d +0.2
Sentiment59 · Δ7d -5.8
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
69
26% active weight
Current posture
7d trendSoftening
Δ7d
+6.4
Δ21d
+2.2
Value
60
39% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+1.1
Sentiment
59
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.8
Δ21d
+4.7
Why this grade
Composite grade A. Momentum 69.1 / Value 59.9 / Sentiment 59.4
Fundamentals (TTM)As of 2026-07-23
Fundamentals (TTM)
As of 2026-07-23
Market Cap
$618.94M
Beta
0.96
Shares Out
22.56M
P/E (TTM)
38.8
P/S (TTM)
2.16
P/FCF (TTM)
17.08
Rev YoY
+22.8%
EPS YoY
-37.7%
Gross Margin
+75.7%
Op Margin
+7.4%
Net Debt
-$67.49M
Current Ratio
4.24
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology